FY2025 EPS Estimate for ProQR Therapeutics Raised by Analyst

ProQR Therapeutics (NASDAQ:PRQR) – Investment analysts at Chardan Capital boosted their FY2025 earnings estimates for ProQR Therapeutics in a research note issued on Monday, March 24th. Chardan Capital analyst K. Nakae now forecasts that the biopharmaceutical company will post earnings per share of ($0.33) for the year, up from their prior estimate of ($0.34). Chardan Capital has a “Buy” rating and a $4.00 price objective on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

PRQR has been the topic of several other research reports. StockNews.com lowered ProQR Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, November 28th. HC Wainwright increased their price objective on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a research note on Friday, March 14th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a research report on Friday, January 10th. They set an “outperform” rating and a $15.00 target price for the company. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price target on the stock in a research report on Monday, March 10th. Finally, JMP Securities restated a “market outperform” rating and set a $8.00 price objective on shares of ProQR Therapeutics in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, five have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $9.50.

ProQR Therapeutics Price Performance

PRQR opened at $1.43 on Thursday. The stock’s 50 day simple moving average is $2.10 and its 200 day simple moving average is $2.59. The stock has a market cap of $150.45 million, a P/E ratio of -4.47 and a beta of 0.24. ProQR Therapeutics has a 1-year low of $1.43 and a 1-year high of $4.62.

Hedge Funds Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC purchased a new stake in ProQR Therapeutics in the 4th quarter worth approximately $30,000. Invesco Ltd. purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at $32,000. Alpine Global Management LLC acquired a new position in ProQR Therapeutics in the fourth quarter valued at $39,000. Two Sigma Securities LLC purchased a new position in ProQR Therapeutics during the fourth quarter worth about $40,000. Finally, ADAR1 Capital Management LLC acquired a new stake in ProQR Therapeutics in the 4th quarter worth about $54,000. Hedge funds and other institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).